Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.

Sezer, AhmetKilickap, SaadettinGümüş, MahmutBondarenko, IgorÖzgüroğlu, MustafaGogishvili, MirandaTurk, HACI MEHMETCicin, IrfanBentsion, DmitryGladkov, OlegClingan, PhilipSriuranpong, ViroteRizvi, NaiyerGao, BoLi, SiyuLee, SueMcGuire, KristinaChen, Chieh-IMakharadze, TamtaPaydas, SemraNechaeva, MarinaSeebach, FrankWeinreich, David MYancopoulos, George DGullo, GiuseppeLowy, IsraelRietschel, Petra2021-02-182021-02-182021-02-13Sezer A., Kilickap S., Gümüş M., Bondarenko I., Özgüroğlu M., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., -Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.-, Lancet (London, England), cilt.397, ss.592-604, 2021http://hdl.handle.net/20.500.12645/28448Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.Article10.1016/s0140-6736(21)00228-233581821